Isotretinoin is an effective drug for the treatment of acne, but elevated liver enzymes, dyslipidemia, insulin resistance, and type 2 diabetes during isotretinoin therapy have been reported. We recently managed a 28-year-old male outpatient (BMI 24 kg/m^2^) affected by severe facial acne. There was no familial history of diabetes. All laboratory determinations, including hepatic function and fasting plasma glucose (FPG) levels (95 mg/dl), were in the reference range. C-peptide and A1C were not evaluated.

In July 2008, a dermatologist prescribed isotretinoin (30 mg/day) for the patient. After 1 month, the patient had an FPG of 118 mg/dl and a substantially normal lipid profile (total cholesterol \[TC\] 191 mg/dl, HDL cholesterol 34 mg/dl, LDL cholesterol 141 mg/dl, triglyceride \[TG\] levels 82 mg/dl, and normal hepatic parameters). Isotretinoin therapy was confirmed. Two months later, the patient\'s FPG was 147 mg/dl, TC 172 mg/dl, HDL cholesterol 29 mg/dl, LDL cholesterol 120 mg/dl, TG levels 118 mg/dl, with normal liver enzymes. In October 2008, FPG was 191 mg/dl, and in November 2008, the therapy was finally discontinued after the acne healed. FPG was 134 mg/dl, A1C 6.2% (\<4.2%), and C-peptide level 1.09 ng/ml (0.9--3.9). We prescribed a low--glycemic index diet with no hypoglycemic drugs.

One month after isotretinoin withdrawal, the patient showed FPG 121 mg/dl, TC 159 mg/dl, HDL cholesterol 49 mg/dl, LDL cholesterol 98 mg/dl, TG 57 mg/dl, normal hepatic parameters, and a slight weight loss (−2 kg; BMI 23.4 kg/m^2^). In January 2009, C-peptide was reduced to 1.0 ng/ml; the patient was negative for anti-islet cell antibodies though positive (5.7 IU/ml) for GAD antibodies. After 3 months of well-being, during which the patient failed to perform the recommended visits and blood exams, he complained of polydipsia, polyuria, and weight loss (−4 kg) with FPG 217 mg/dl, A1C 9.1% (\<6.4%), TC 169 mg/dl, HDL cholesterol 50 mg/dl, LDL cholesterol 106 mg/dl, TG 63 mg/dl, C-peptide 0.8 ng/ml, and GAD antibodies 6.8 IU/ml, without ketosis. Regarding the poor glycemic control and low C-peptide levels, we prescribed intensive insulin therapy with lispro at mealtime and glargine at bedtime. After 3 months the patient regained weight (6.7 kg, BMI 24.2 kg/m^2^), with a better metabolic control (FPG 121 mg/dl, A1C 6.4%, TC 182 mg/dl, HDL cholesterol 48 mg/dl, LDL cholesterol 121 mg/dl, TG 66 mg/dl, and C-peptide 0.6 ng/ml).

An insulin resistance worsening induced by isotretinoin therapy, probably related to higher lipid oxidation through the Randle cycle, is observed by Koistinen et al. ([@B1]). In fact, isotretinoin induced a reversible decrease in insulin sensitivity, evaluated by euglycemic clamp and the pathognomonic insulin resistance dyslipidemia. An association between metabolic syndrome and isotretinoin was previously reported ([@B2]). The lipotoxicity, glucotoxicity, and apoptosis of β-cells mediated by high levels of circulating fatty acids ([@B3],[@B4]) are well known.

It is reasonable that latent autoimmune diabetes in adults (LADA) could be clinically revealed by drug-induced insulin resistance. In this case, the only remarkable change of lipid profile consisted in a reduction of HDL cholesterol during isotretinoin treatment; therefore, the previously reported physiopathological hypothesis ([@B1][@B2][@B3]--[@B4]) is not completely supported. However, this is the first report of an association between isotretinoin and an unmasking case of autoimmune diabetes.
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